Recent News

572 News Items found
Nadeem Riaz (left) and Jorge Reis-Filho (right)
Human data and results from mouse experiments suggest that people with BRCA2 mutations may respond well to immunotherapy drugs.
Systems biologist Joao Xavier in his lab
Finding
MSK researchers have shown for the first time that the concentration of different types of immune cells in the blood changes in relation to the presence of different bacterial strains in the gut.
SKI cell biologists Junmei Yi and Xuejun Jiang
In the Lab
Cancers with certain mutations are vulnerable to ferroptosis, a form of iron-dependent cell death.
An illustration of a reel of film
In the Lab
Grab your popcorn and pull up a chair for these video shorts of cell signaling in early mouse development.
MSK immunologist Ming Li.
In the Lab
Targeting the cancer environment, rather than the cancer itself, could be a new avenue for immunotherapy.
MSK developmental biologist Lorenz Studer
Q&A
In an interview in September 2020, Dr. Studer spoke about what he hopes he and his fellow investigators can accomplish with this generous support.
Regulatory proteins (gold balls) bind to enhancer regions (light blue) and promoter regions (pink) of DNA to form clusters that enable transcription (purple).
Scientists at the Sloan Kettering Institute are learning how far-flung regions of genes connect to start the process of making proteins.
An illustration of a beta-amyloid plaque among the neurons in a brain.
Article
An enzyme that contributes to plaque formation in the brain also serves as a first line of defense against bacteria and viruses, suggesting a link between the two.
Black blobs on a white background
In the Lab
Researchers shed light on how aberrant cell division can cause the kind of mutations often found in cancer cells.
Having two mutated copies of the TP53 gene — as opposed to a single mutated copy — is associated with worse outcomes in a blood cancer called myelodysplastic syndrome, according to a new study led by researchers at Memorial Sloan Kettering.